Abivax has filed the paperwork for an IPO in Paris. The listing is intended to give Abivax the cash to fund mid- to late-phase trials of its two lead candidates, a therapeutic vaccine against hepatitis B and a small-molecule inhibitor of HIV replication.

…read more

Source: Abivax files for IPO to finance trials of HepB vaccine, HIV antiviral


0 No comments